leisure time -WSS

leisure time

author：entertainment 2025-09-03 03:38:14 - browse：52

Kara Coluccio, a managing partner at Perspective Group poses for a portrait. -- health coverage from STAT — Kara Coluccio, a managing partner at Perspective Group, says the job market for biotech executives has gotten much tighter. Jessica Rinaldi/Globe Staff

When Crystal Shih Byers left her job at Novartis in 2020, she was excited to make the leap into a smaller startup.

Byers had spent almost nine years at Novartis, most recently helping lead a group that worked on gene therapy. But pharmaceutical companies are large and complex, and she craved more immediate impact. “I was looking for a place where I could be in the room,” she says. She wanted more autonomy, and to feel like her work would reach patients sooner.

At the time, biotech startups were rolling in cash and seeking to capture some of the magic that had fueled Moderna’s meteoric rise. They handed out lots of logo-embossed swag. “Investors were putting a lot of money into stupid science,” Byers says. “There were a lot of companies that lasted for a lot longer than I thought they would on very little data.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Healthy food access boosts outcomes in two studies

focus

hotspot

WSS

Ventyx halts psoriasis drug development after lackluster trial results

Medicare Advantage plans can’t deny care with AI, CMS warns

AstraZeneca stays mum on Medicare drug pricing negotiations

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Cano Health’s bankruptcy is a warning for Medicare Advantage

Johnson & Johnson sued for allegedly overpaying for workers' drugs

hotspot

leisure time

focus

Sports medicine is finally prioritizing gender equality

Cano Health’s bankruptcy is a warning for Medicare Advantage

How one medical school became remarkably diverse

Ventyx halts psoriasis drug development after lackluster trial results

23andMe had bad news about my health. I wish a person had delivered it

First transplant of an entire human eye performed

Novavax promises a turnaround & Lilly roils the obesity market

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Psychedelics group wrestles with new pharma identity

NIH chief: government has fallen behind pharma on clinical trials

focus

Carbon Health diabetes program, a test of data

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Top private equity targets in 2023: cardiology, clinical trials, lasers

Why CTE doesn’t keep Americans from enjoying the Super Bowl

The CDC's new social media misinformation war

Medical school prerequisites are outdated

hotspot

focus

hotspot

hotspot